[TO BE PUBLISHED IN THE GAZETTE OF INDIA, EXTRAORDINARY, PART II, SECTION 3, SUB-SECTION (i)]

GOVERNMENT OF INDIA
MINISTRY OF FINANCE
(Department of Revenue)

Notification No. 09/2025-Customs

New Delhi, the 1st February, 2025

G.S.R….(E).- In exercise of the powers conferred by sub-section (1) of section 25 of the Customs Act, 1962 (52 of 1962), the Central Government, on being satisfied that it is necessary in the public interest so to do, hereby makes the following further amendments in the notification of the Government of India in the Ministry of Finance (Department of Revenue) No. 16/2017-Customs, dated the 20th April, 2017, published in the Gazette of India, Extraordinary, Part II, Section 3, Sub-section (i), *vide* number G.S.R. 394(E), dated the 20th April, 2017, namely :-

In the said notification, in the TABLE, after serial number 52 and the entries relating thereto, the following serial numbers and the entries shall be inserted, namely :-

(1)	(2)	(3)	(4)
"53.	Pembrolizumab	Key- PAP 1.0	MSD Pharmaceuticals
54.	Pembrolizumab	KIRAN	MSD Pharmaceuticals
55.	Lorlatinib	LorbriquaCare	Pfizer Products India Private Ltd.
56.	Dacomitinib	DacoCare	Pfizer Products India Private Ltd.
57.	Inotuzumab Ozogamicin	HemaCare	Pfizer Products India Private Ltd.
58.	Ribociclib	UMAANG	Novartis Healthcare Pvt. Ltd.
59.	Dabrafenib	UMAANG	Novartis Healthcare Pvt. Ltd.
60.	Selumetinib	AstraZeneca Pharma PAP	AstraZeneca Pharma India Limited
61.	Benralizumab	AstraZeneca Pharma PAP	AstraZeneca Pharma India Limited
62.	Fulvestrant	AstraZeneca Pharma PAP	AstraZeneca Pharma India Limited
63.	Acalabrutinib	AstraZeneca Pharma PAP	AstraZeneca Pharma India Limited
64.	Olaparib	AstraZeneca Pharma PAP	AstraZeneca Pharma India Limited

65.	Amivantamab	Johnson and Johnson PAP	Johnson & Johnson Pvt. Ltd.
66.	Teclistamab	Johnson and Johnson PAP	Johnson & Johnson Pvt. Ltd.
67.	Ustekinumab	Johnson and Johnson PAP	Johnson & Johnson Pvt. Ltd.
68.	Daratumumab And hyaluronidase-fihj	Johnson and Johnson PAP	Johnson & Johnson Pvt. Ltd.
69.	Ibrutinib	Johnson and Johnson PAP	Johnson & Johnson Pvt. Ltd.
70.	Bortezomib	Johnson and Johnson PAP	Johnson & Johnson Pvt. Ltd.
71.	Daratumumab	Johnson and Johnson PAP	Johnson & Johnson Pvt. Ltd.
72.	Cetuximab	Rainbow PAP	Merck Specialties Pvt. Ltd.
73.	Avelumab	My Bavencio Assist Program	Merck Specialties Pvt. Ltd.
74.	Tepotinib	My Tepmetko Patient Access Program	Merck Specialties Pvt. Ltd.
75.	Brentuximab Vedotin	Takeda PAP	Takeda Biopharmaceuticals India Pvt. Limited
76.	Vedolizumab	Takeda PAP	Takeda Biopharmaceuticals India Pvt. Limited
77.	Velaglucerase Alpha	Takeda PAP	Takeda Biopharmaceuticals India Pvt. Limited
78.	Agalsidase Alpha	Takeda PAP	Takeda Biopharmaceuticals India Pvt. Limited
79.	Idursulphase	Takeda PAP	Takeda Biopharmaceuticals India Pvt. Limited
80.	Mepolizumab	GSK Pharmaceuticals Limited	GSK Pharmaceuticals Limited
81.	Alectinib	The Blue Tree	Roche Products India Private Ltd.
82.	Risdiplam Powder	The Blue Tree	Roche Products India Private Ltd.
83.	Emicizumab	The Blue Tree	Roche Products India Private Ltd.

84.	Atezolizumab	The Blue Tree	Roche Products India Private Ltd.
85.	Pertuzumab + trastuzumab	The Blue Tree	Roche Products India Private Ltd.
86.	Ocrelizumab	The Blue Tree	Roche Products India Private Ltd.
87.	Polatuzumab vedotin	The Blue Tree	Roche Products India Private Ltd.
88.	Faricimab	The Blue Tree	Roche Products India Private Ltd.
89.	Luspatercept	Bristol-Myers Patient Assistance Program	Bristol-Myers Squibb India Pvt. Ltd. ".

2. This notification shall come into force on the 2nd day of February, 2025.

[F. No. 334/03/2025-TRU]

(Amreeta Titus)
Deputy Secretary to the Government of India

Note: The principal notification No. 16/2017-Customs, dated the 20th April, 2017 was published in the Gazette of India, Extraordinary, Part II, Section 3, Sub-Section (i), *vide* number G.S.R. 394(E), dated the 30th June, 2017 and last amended *vide* notification No. 38/2024-Customs, dated the 23rd July, 2024, published in the Gazette of India, Extraordinary, Part II, Section 3, Sub-section (i), *vide* number G.S.R. 441(E), dated the 23rd July, 2024.